Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..

Piramal Pharma Ltd. is trading above its 100 day SMA of 208.5

Piramal Pharma Ltd.

20 Mar 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release - Piramal Critical Care and BrePco announces MHRA approval for Neoatricon in the UK.

pdf

Piramal Pharma Ltd.

11 Mar 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Piramal Pharma Ltd.

20 Feb 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Submission of copy of newspaper advertsiment for Postal Ballot Notice

pdf

Piramal Pharma Ltd.

19 Feb 2025

215.00

-0.56%

AGM

Piramal Pharma Ltd - 543635 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

BSE India

Submission of Postal Ballot Notice & Intimation of Remote E-Voting

pdf

Piramal Pharma Ltd.

18 Feb 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation under Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regualtions") - US FDA Inspection at Piramal Pharma''s facility located at Turbhe.

pdf

Piramal Pharma Ltd.

18 Feb 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Intimation For Change In Domain Name And Generic E-Mail ID …

BSE India

Intimation for change in Domain name and Generic e-mail ID of Registrar and Share Transfer Agent (RTA) of the company

pdf

Piramal Pharma Ltd.

17 Feb 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Piramal Pharma Ltd.

31 Jan 2025

215.00

-0.56%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Extension of timeline communicated for sale of Company''s Unit situated at Thane.

pdf

VOTE: Is Piramal Pharma Ltd. worth buying?

373 Votes:

Buy 82.84%

Sell 11.26%

Hold 5.9%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf link